Intravascular Large B Cell Lymphoma with CNS Involvement Successfully Treated with High-Dose Methotrexate and High-Dose Ara-C Based CNS-Directed Chemoimmunotherapy Alternating with Anthracycline Based Chemoimmunotherapy

References

• Jaffe ES. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Iarc. Vol. 3; 2001.
   Google Scholar
• Ponzoni M, Ferreri AJM, Campo E, et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol. 2007;25(21):3168–3173. doi:10.1200/JCO.2006.08.2313
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Campo E, Ambrosetti A, et al. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Ann Oncol. 2004;15(8):1215–1221. doi:10.1093/annonc/mdh274
   PubMed Web of Science ®Google Scholar
• Ponzoni M, Arrigoni G, Gould VE, et al. Lack of CD 29 (β1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol. 2000;31(2):220–226. doi:10.1016/S0046-8177(00)80223-3
   PubMed Web of Science ®Google Scholar
• Starr JS, Jiang L, Li Z, et al. CD47 and osteopontin expression in diffuse large B-cell lymphoma with nodal and intravascular involvement. Clin Lymphoma Myeloma Leuk. 2013;13(5):597–601. doi:10.1016/j.clml.2013.05.001
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Jamieson CHM, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271–285. doi:10.1016/j.cell.2009.05.046
   PubMed Web of Science ®Google Scholar
• Ponzoni M, Campo E, Nakamura S. Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks. Blood. 2018;132(15):1561–1567. doi:10.1182/blood-2017-04-737445
   PubMed Web of Science ®Google Scholar
• Ferry J, Harris NL, Picker LJ, et al. Intravascular lymphomatosis (malignant angioendotheliomatosis). A B-cell neoplasm expressing surface homing receptors. Mod pathol. 1988;1(6):444–452.
   PubMed Web of Science ®Google Scholar
• Kato M, Ohshima K, Mizuno M, et al. Analysis of CXCL9 and CXCR3 expression in a case of intravascular large B-cell lymphoma. J Am Acad Dermatol. 2009;61(5):888–891. doi:10.1016/j.jaad.2009.02.007
   PubMed Web of Science ®Google Scholar
• Alon R, Shulman Z. Chemokine triggered integrin activation and actin remodeling events guiding lymphocyte migration across vascular barriers. Exp Cell Res. 2011;317(5):632–641. doi:10.1016/j.yexcr.2010.12.007
   PubMed Web of Science ®Google Scholar
• Kasuya A, Fujiyama T, Shirahama S, et al. Decreased expression of homeostatic chemokine receptors in intravascular large B-cell lymphoma. Eur J Dermatol. 2012;22(2):272–273. doi:10.1684/ejd.2012.1639
   PubMed Web of Science ®Google Scholar
• Kinoshita M, Izumoto S, Hashimoto N, et al. Immunohistochemical analysis of adhesion molecules and matrix metalloproteinases in malignant CNS lymphomas: a study comparing primary CNS malignant and CNS intravascular lymphomas. Brain Tumor Pathol. 2008;25(2):73–78. doi:10.1007/s10014-008-0232-x
   PubMed Web of Science ®Google Scholar
• Shimada K, Shimada S, Sugimoto K, et al. Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma. Leukemia. 2016;30(7):1568–1579. doi:10.1038/leu.2016.67
   PubMed Web of Science ®Google Scholar
• Murase T, Nakamura S, Kawauchi K, et al. An Asian variant of intravascular large B‐cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B‐cell lymphoma associated with haemophagocytic syndrome. Br J Haematol. 2000;111(3):826–834.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang Y, Zhu Y, et al. Prognosis of Intravascular Large B Cell Lymphoma (IVLBCL): analysis of 182 patients from global case series. Cancer Manag Res. 2020;12:10531. doi:10.2147/CMAR.S267825
   PubMed Web of Science ®Google Scholar
• Shimada K, Kiyoi H. Current progress and future perspectives of research on intravascular large B-cell lymphoma. Cancer Sci. 2021;112(10):3953–3961. doi:10.1111/cas.15091
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Dognini GP, Bairey O, et al. The addition of rituximab to anthracycline‐based chemotherapy significantly improves outcome in ‘Western’patients with intravascular large B‐cell lymphoma. Br J Haematol. 2008;143(2):253–257. doi:10.1111/j.1365-2141.2008.07338.x
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Dognini GP, Govi S, et al. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? J Clin Oncol. 2008;26(31):5134–5137. doi:10.1200/JCO.2008.19.1841
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Tanaka H, Suyama K, et al. Secondary central nerve system lymphoma with intratumoral hemorrhage suggested as intravascular lymphoma by autopsy: a case report. J Clin Med Res. 2017;9(11):953–957. doi:10.14740/jocmr3177w
   PubMedGoogle Scholar
• Gan LP, Ooi W, Lee H, et al. A case of large B-cell intravascular lymphoma in the brain. Surg Neurol Int. 2013;4:99. doi:10.4103/2152-7806.115709
   PubMedGoogle Scholar
• Marino D, Sicurelli F, Cerase A, et al. Fulminant intravascular lymphomatosis mimicking acute haemorrhagic leukoencephalopathy. J Neurol Sci. 2012;320(12):141–144. doi:10.1016/j.jns.2012.05.043
   PubMed Web of Science ®Google Scholar
• Koujanian S, Al-Rawaf S, Zang E, Provias J. Intravascular large B-cell lymphoma of the central nervous system, a masquerader on radiography and clinical presentation: a case report. Hum Pathol. 2020;19:200297.
   Google Scholar
• Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217–e227. doi:10.1016/S2352-3026(16)00036-3
   PubMed Web of Science ®Google Scholar
• Mead GM, Bleehen NM, Gregor A, et al. A medical research council randomized trial in patients with primary cerebral non‐Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer. 2000;89(6):1359–1370. doi:10.1002/1097-0142(20000915)89:6<1359::AID-CNCR21>3.0.CO;2-9
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Campo E, Seymour JF, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’ 1. Br J Haematol. 2004;127(2):173–183. doi:10.1111/j.1365-2141.2004.05177.x
   PubMed Web of Science ®Google Scholar
• Shimada K, Matsue K, Yamamoto K, et al. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol. 2008;26(19):3189–3195. doi:10.1200/JCO.2007.15.4278
   PubMed Web of Science ®Google Scholar
• Takahashi H, Nishimaki H, Nakanishi Y, et al. Clinical impact of central nervous system‐directed therapies on intravascular large B‐cell lymphoma: a single institution’s experience. eJHaem. 2022. doi:10.1002/jha2.380
   Google Scholar
• Shimada K, Murase T, Matsue K, et al. Central nervous system involvement in intravascular large B‐cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci. 2010;101(6):1480–1486. doi:10.1111/j.1349-7006.2010.01555.x
   PubMed Web of Science ®Google Scholar
• Chen R, Singh G, McNally JS, et al. Intravascular lymphoma with progressive CNS hemorrhage and multiple dissections. Case Rep Neurol Med. 2020;2020:6134830. doi:10.1155/2020/6134830
   PubMed Web of Science ®Google Scholar
• Chwalisz BK, Douglas VP, Douglas KAA, et al. Episodic visual distortions and stroke-like symptoms in a 56-year-old man with intravascular lymphoma. J Neuro-Ophthalmol. 2020;40(2):265–270. doi:10.1097/WNO.0000000000000900
   PubMed Web of Science ®Google Scholar
• Cruto C, Taipa R, Monteiro C, et al. Multiple cerebral infarcts and intravascular central nervous system lymphoma: a rare but potentially treatable association. J Neurol Sci. 2013;325(1–2):183–185. doi:10.1016/j.jns.2012.10.012
   PubMed Web of Science ®Google Scholar
• Shimada K, Yamaguchi M, Atsuta Y, et al. Favorable Outcomes of newly diagnosed intravascular large B-cell lymphoma patients treated with R-CHOP combined with high-dose methotrexate plus intrathecal chemotherapy: results from a multicenter phase 2 trial (PRIMEUR-IVL). Blood. 2019;134:350. doi:10.1182/blood-2019-126798
   Web of Science ®Google Scholar
• Shimada K, Yamaguchi M, Atsuta Y, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(4):593–602. doi:10.1016/S1470-2045(20)30059-0
   PubMed Web of Science ®Google Scholar
• Murase T, Yamaguchi M, Suzuki R, et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood. 2007;109(2):478–485. doi:10.1182/blood-2006-01-021253
   PubMed Web of Science ®Google Scholar